



Jonathan Linden

Principal

jonathan.linden@faberlawgroup.com

781 795 4712 direct

he/him

Industry Experience

Senior Counsel

Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

Deputy General Counsel

Brookstone, Inc.

Product Counsel

Apple, Inc.

Jon skillfully handles complex transactions and agreements in the life sciences and technology industries. He guides life sciences clients through research and development, as well as manufacturing. He also helps his clients negotiate effective product licensing transactions with other commercial entities and academic research institutions. Jon's considerable experience also includes trans-border deals, where he has negotiated and successfully completed product licenses involving European, Asian and U.S.-based drug companies, including related supply agreements.

He also advises technology clients on complex software license and related support agreements, as well as IT platform license and support agreements for drug development, healthcare services, database services and other applications.

EXPERIENCE

Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

Senior Counsel

- Handled legal matters for the company in many areas, including licensing biotechnology and software technologies and advising its clinical and manufacturing operations
- Primary business attorney for one of Millennium's key technology alliances
- Helped to mentor and train contracts associates

Brookstone

Deputy General Counsel

- Helped develop systems for intellectual property protection for the company's proprietary products

Bar Admissions

- California
- Massachusetts

Education

- Stanford Law School, J.D., with Distinction
- Brown University, A.B., *magna cum laude* with Honors



Jonathan Linden (continued)

Apple

Software and technical counsel

- Provided legal counsel for a variety of Apple product lines

Folger & Levin

Business Associate

- Several years of publishing industry experience

RECENT CLIENT WORK

- Collaboration agreement between Biogen and Proteostasis Therapeutics, Inc., for the development of drugs to combat Alzheimer's and other neurodegenerative diseases (involved amendment of a pre-existing license agreement with Harvard University)
- In-license of antibody screening and development platform by Biogen from Adimab, LLC
- License and collaboration agreement between Taiwanese company PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. (now Ipsen Pharma) involving grant back from PharmaEngine to Merrimack of research, development and commercialization rights to an oncology drug candidate in exchange for milestones and royalties
- Exclusive in-license by Taiwanese company PharmaEngine, Inc. from French company Nanobiotix, S.A. of Asian research, development and commercialization rights to nanotherapy oncology treatment
- Expansion from Asia-only to worldwide of Japanese company Solasia Pharma K.K.'s exclusive license with ZIOPHARM Oncology, Inc. for research, development and commercialization of oncology product
- Exclusive in-license by Corbus Pharmaceuticals Holdings, Inc. from Jenrin Discovery LLC of exclusive worldwide rights to more than 600 compounds targeting the endocannabinoid system
- Supervision of Faber's clinical trial contracting efforts for Portola Pharmaceuticals, Inc., including Portola's approved products Bevixxa® (betrixaban) and Andexxa® (coagulation factor Xa (recombinant), inactivated-zhzo)
- Amendment of existing agreement between Arsanis, Inc. and Adimab, LLC (involved coordination with a grant agreement with the Bill & Melinda Gates Foundation)
- Review and negotiation of numerous agreements for provision of genetic testing and analysis services for client Personalis, Inc.

